# Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC

> **NCT02531425** · PHASE1 · COMPLETED · sponsor: **OncoSec Medical Incorporated** · enrollment: 10 (actual)

## Conditions studied

- ER-Negative PR-Negative HER2-Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** IT-pIL12-EP

## Key facts

- **NCT ID:** NCT02531425
- **Lead sponsor:** OncoSec Medical Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02531425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02531425, "Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02531425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*